For Public

An Innovative Simple Blood Test to Detect Colorectal Cancer Early

Colorectal cancer is a major health concern worldwide. Early detection is crucial for better treatment outcomes. ColonAiQ is a groundbreaking test that makes it easier to detect colorectal cancer early. Here’s what you need to know:

What is ColonAiQ®?

  • Non-Invasive Test: ColonAiQ uses a simple blood test to detect signs of colorectal cancer.
  • Advanced Technology: It analyzes tiny DNA changes in your blood linked to cancer.

Why is Early Detection Important?

  • Better Treatment: Detecting cancer early increases the chances of successful treatment.
  • Increased Survival Rates: Early detection can significantly improve survival rates

How Does ColonAiQ® Work?

  • Sample Collection: A small blood sample is taken.
  • DNA Extraction: Special techniques are used to isolate DNA from the blood.
  • DNA Analysis: The DNA is examined for specific changes (methylation) linked to colorectal cancer.

Key Benefits of ColonAiQ®

  • High Accuracy: ColonAiQ has shown to be highly accurate in detecting colorectal cancer.
  • Sensitivity: 86-89% (ability to correctly identify those with cancer)
  • Specificity: 92-93% (ability to correctly identify those without cancer)
  • Early Detection: More effective in finding cancer in its early stages compared to traditional methods.

ColonAiQ® vs. CEA (Carcinoembryonic Antigen)

  • Overall Accuracy: ColonAiQ® 88.3%, CEA 59.7%
  • Early Stage Detection: ColonAiQ® 85.7%, CEA 28.6%

ColonAiQ® vs. FIT (Fecal Immunochemical Test)

  • Overall Accuracy: ColonAiQ® 85.1%, FIT 72.0%
  • Early Stage Detection: ColonAiQ® 78.3%, FIT 52.2%

Additional Benefits

  • Relapse Monitoring: ColonAiQ® can also help monitor patients for cancer relapse after treatment, providing an early warning if cancer returns.

ColonAiQ® vs. SEPT9

  • Overall Accuracy: ColonAiQ® 85.5%, SEPT9 38.2%
  • Early Stage Detection: ColonAiQ® 91.7%, SEPT9 16.7%

Where Has ColonAiQ® Been Tested?

  • Top Hospitals: ColonAiQ has been validated in leading hospitals and medical centers in China, including Fudan University Shanghai Cancer Center and Zhongshan Hospital.
  • Clinical Trials: It has been tested in multiple studies with large sample sizes, proving its reliability and effectiveness.

Conclusion

ColonAiQ offers a revolutionary, non-invasive way to detect colorectal cancer early and accurately. By choosing ColonAiQ, you are opting for a test that can save lives through early detection and improved treatment outcomes.
For more information about ColonAiQ, talk to your healthcare provider.
  • Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
  • Singapore Cancer Network (SCAN) guidelines for Systemic therapy of colorectal cancer. (2015). Annals, Academy of Medicine, Singapore/Annals of the Academy of Medicine, Singapore, 44(10), 379–387. https://doi.org/10.47102/annals-acadmedsg.v44n10p379
    https://doi.org/10.1053/j.gastro.2021.08.054
  • Cai, G., Cai, M., Feng, Z., Liu, R., Liang, L., & Zhou, P. (2021). A Multilocus Blood-Based Assay Targeting Circulating Tumor DNA Methylation Enables Early Detection and Early Relapse Prediction of Colorectal Cancer. Gastroenterology, 161(6), 2053-2056.e2. https://doi.org/10.1053/j.gastro.2021.08.054

Contact Us for Screening Options

CONTACT NOW

Saver’s Med Pte Ltd is the exclusive distributor for Singlera’s ColonAiQ® in Singapore and the Philippines.

Linkedin X-twitter Facebook Instagram Pinterest

Important Links

CONTACT INFORMATION

© 2024 Saversmed. All rights reserved.

Get In Touch

Kindly Note

ColonAiQ is undergoing Health Sciences Authority (HSA) review for registration in Singapore and the Philippines.

Sign up for our waitlist to be among the first to be notified when ColonAiQ becomes available! Please leave your contact details.